HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Euglycemic agent-mediated hypothalamic transcriptomic manipulation in the N171-82Q model of Huntington disease is related to their physiological efficacy.

Abstract
Our aim was to employ novel analytical methods to investigate the therapeutic treatment of the energy regulation dysfunction occurring in a Huntington disease (HD) mouse model. HD is a neurodegenerative disorder that is characterized by progressive motor impairment and cognitive alterations. Changes in neuroendocrine function, body weight, energy metabolism, euglycemia, appetite function, and gut function can also occur. It is likely that the locus of these alterations is the hypothalamus. We determined the effects of three different euglycemic agents on HD progression using standard physiological and transcriptomic signature analyses. N171-82Q HD mice were treated with insulin, Exendin-4, and the newly developed GLP-1-Tf to determine whether these agents could improve energy regulation and delay disease progression. Blood glucose, insulin, metabolic hormone levels, and pancreatic morphology were assessed. Hypothalamic gene transcription, motor coordination, and life span were also determined. The N171-82Q mice exhibited significant alterations in hypothalamic gene transcription signatures and energy metabolism that were ameliorated, to varying degrees, by the different euglycemic agents. Exendin-4 or GLP-1-Tf (but not insulin) treatment also improved pancreatic morphology, motor coordination, and increased life span. Using hypothalamic transcription signature analyses, we found that the physiological efficacy variation of the drugs was evident in the degree of reversal of the hypothalamic HD pathological signature. Euglycemic agents targeting hypothalamic and energy regulation dysfunction in HD could potentially alter disease progression and improve quality of life in HD.
AuthorsBronwen Martin, Wayne Chadwick, Wei-na Cong, Nick Pantaleo, Caitlin M Daimon, Erin J Golden, Kevin G Becker, William H Wood 3rd, Olga D Carlson, Josephine M Egan, Stuart Maudsley
JournalThe Journal of biological chemistry (J Biol Chem) Vol. 287 Issue 38 Pg. 31766-82 (Sep 14 2012) ISSN: 1083-351X [Electronic] United States
PMID22822065 (Publication Type: Journal Article, Research Support, N.I.H., Intramural)
Chemical References
  • Blood Glucose
  • Insulin
  • Peptides
  • Serotonin Plasma Membrane Transport Proteins
  • Slc6a4 protein, mouse
  • Venoms
  • Glucagon-Like Peptide 1
  • Exenatide
Topics
  • Animals
  • Blood Glucose (metabolism)
  • Diabetes Mellitus (metabolism)
  • Drug Design
  • Exenatide
  • Glucagon-Like Peptide 1 (metabolism)
  • Huntington Disease (blood, genetics)
  • Hypothalamus (metabolism)
  • Insulin (metabolism)
  • Male
  • Mice
  • Mice, Transgenic
  • Models, Animal
  • Models, Neurological
  • Oligonucleotide Array Sequence Analysis
  • Pancreas (metabolism)
  • Peptides (metabolism)
  • Serotonin Plasma Membrane Transport Proteins (genetics)
  • Transcription, Genetic
  • Venoms (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: